scFv(CEA)-CD28-41BB-CD3zeta CAR-T Lentivirus

The scFv(CEA)-CD28-41BB-CD3zeta CAR-T lentiviral vector contains a third-generation anti-CEA chimeric antigen receptor, meticulously designed for potent activation, durability, and safety. The core structure of this CAR includes: an anti-CEA single-chain variable fragment for highly specific antigen recognition; a CD28 transmembrane and co-stimulatory module to drive rapid activation and proliferation; a 4-1BB (CD137) co-stimulatory domain to enhance persistence and metabolic fitness; and a CD3ζ signaling domain to initiate robust T cell effector functions. This dual co-stimulatory structure is designed to balance immediate cytotoxic potency with long-term memory formation, helping to mitigate premature exhaustion while maintaining anti-tumor activity. The lentiviral delivery platform supports stable genomic integration and durable CAR expression in human T cells and incorporates widely used safety features, such as self-inactivating LTRs and split-packaging systems, to reduce the risk of replication-competent lentivirus.

This lentiviral system is broadly applicable to preclinical research and translational development targeting CEA-expressing malignancies, including colorectal cancer, gastric cancer, pancreatic cancer, cholangiocarcinoma, and certain lung and breast cancers. It can efficiently generate CEA-targeted CAR-T cells for in vitro cytotoxicity, cytokine release profiling, and resistance mechanism studies, as well as in vivo efficacy and safety assessments in xenograft and patient-derived models. Researchers can utilize this system to explore T cell activation thresholds, exhaustion trajectories, memory differentiation, and migration within the solid tumor microenvironment—critical issues in overcoming challenges such as antigen heterogeneity, stromal exclusion, and immunosuppressive signaling. The vector''s stable expression supports longitudinal studies of persistence, functional durability, and relapse dynamics, and can be integrated into workflows evaluating therapeutic strategies combined with checkpoint inhibitors, oncolytic virus platforms, targeted therapies, or cytokine support.